Combination of ultra-rapid DNA purification (PURE) and loop-mediated isothermal amplification (LAMP) for rapid detection of Trypanosoma cruzi DNA in dried blood spots

PLoS Negl Trop Dis. 2023 Apr 14;17(4):e0011290. doi: 10.1371/journal.pntd.0011290. eCollection 2023 Apr.

Abstract

Background: Chagas disease or American trypanosomiasis, a neglected tropical disease, is a persistent Public Health problem in Latin America and other, non-endemic, countries. Point-of-care (POC) sensitive methods are still needed to improve and extend early diagnosis in acute infections such as congenital Chagas disease. The objective of this study was to analytically evaluate in the lab the performance of a qualitative POC molecular test (Loop-mediated isothermal amplification (LAMP), Eiken, Japan) for rapid diagnosis of congenital Chagas disease employing FTA cards or Whatman 903 filter paper as solid supports for small-scale volumes of human blood.

Methodology/principal findings: We used human blood samples artificially infected with cultured T. cruzi strains to assess the analytical performance of the test in comparison with liquid blood anticoagulated with heparin. The DNA extraction process was evaluated using the ultrarapid purification system PURE manufactured by Eiken Chemical Company (Tokio, Japan) over artificially infected liquid blood or different amounts of dried blood spot (DBS) 3- and 6-mm pieces of FTA and Whatman 903 paper. LAMP was performed on a AccuBlock (LabNet, USA) heater or in the Loopamp LF-160 incubator (Eiken, Japan), and visualization of results was either done at naked eye, using the LF-160 device or P51 Molecular Fluorescence Viewer (minipcr bio, USA). Best conditions tested showed a limit of detection (LoD) with 95% accuracy (19/20 replicates) of 5 and 20 parasites/mL, respectively for heparinized fluid blood or DBS samples. FTA cards showed better specificity than Whatman 903 filter paper.

Conclusions/significance: Procedures to operate LAMP reactions from small volumes of fluid blood or DBS in FTA were standardized for LAMP detection of T. cruzi DNA. Our results encourage prospective studies in neonates born to seropositive women or oral Chagas disease outbreaks to operationally evaluate the method in the field.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chagas Disease* / congenital
  • Chagas Disease* / diagnosis
  • Female
  • Humans
  • Infant, Newborn
  • Nucleic Acid Amplification Techniques / methods
  • Prospective Studies
  • Sensitivity and Specificity
  • Trypanosoma cruzi* / genetics

Supplementary concepts

  • LAMP assay

Grants and funding

This study was funded by the Global Health Innovative Technology Fund (GHIT Fund, G2020-203; Tokyo, Japan) to JAP and AGS. We would also like to acknowledge the co-funding by Fundación Mundo Sano, and the support from PAHO through the Small Grant Programme (TDR Chagas Project LEG ID 39002) to AGS, ERANet LAC Joint Call 2016-2017 Cochaco to AGS, and PICT 2020-0862 from the Ministry of Science and Technology, Argentina to AGS and SAL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.